CRISPR Therapeutics AG (CRSP) is a publicly traded Healthcare sector company. As of July 5, 2026, CRSP trades at $60.08 with a market cap of $5.92B and a P/E ratio of -9.69. CRSP moved +8.00% today. Year to date, CRSP is +12.95%; over the trailing twelve months it is +16.28%. Its 52-week range spans $30.04 to $78.48. Analyst consensus is buy with an average price target of $73.85. Rallies surfaces CRSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for CRSP, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $60.08 |
| Market Cap | $5.92B |
| P/E Ratio | -9.69 |
| EPS | $-6.20 |
| Dividend Yield | 0.00% |
| 52-Week High | $78.48 |
| 52-Week Low | $30.04 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.10M |
| Net Income | $-568.53M |
| Gross Margin | 0.00% |
14 analysts cover CRSP: 0 strong buy, 9 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $73.85.